Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
Margaret O. Ilomuanya, Ayotunde T. Hameedat, Edidiong Nnamso Akang, Sabdat Ekama, Boladale O. Silva, Sulaimon Akanmu
Abstract
Abstract Background Sexual transmission of HIV is the most common means of acquiring the disease. Topical microbicides have been investigated to prevent transmission. This study will use a specific entry inhibitor, maraviroc, and a nucleotide reverse transcriptase inhibitor (NRTI), tenofovir, a dual combination which will provide a synergist effect that can enhance the efficacy of HIV microbicides via a mucoadhesive dual compartment bigel. Bigel formulation via hydrogel organogel linkages were developed and evaluated for their physicochemical characteristics, safety, and anti-HIV efficacy. In vitro diffusion studies were performed with Franz diffusion cells having effective diffusion surface area of 1.76cm 2 and receiver chamber volume of 15mL. Result The bigel formulations showed a viscosity ranging from 14179 to 14560 cPs and had a good spreadability and acidic pH in the range of 4.0 ± 0.34 to 5.2 ± 0.18. The bigel formulations showed good anti-HIV activity at a concentration of 0.1 μg/mL. The in vitro release study of maraviroc from the bigel formulations showed a release rate ranging from 2.675 to 3.838 μg/cm 2 /min ½ while the release rate for tenofovir ranged from 3.475 to 3.825 μg/cm 2 /min ½ . The bigel formulations were non-toxic to the human vagina as there was < 1 log 10 change in Lactobacilli crispatus viability. Conclusion This study successfully developed a dual compartment bigel containing maraviroc and tenofovir. BG C was found to be stable and safe towards vaginal and rectal epithelium, and it actively prevented HIV transmission. This bigel has the potential for long-term pre-exposure prophylaxis prevention of HIV transmission.